Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.

Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA.

J Acquir Immune Defic Syndr. 2019 Apr 29. doi: 10.1097/QAI.0000000000002094. [Epub ahead of print]

PMID:
31107304
2.

Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease.

Scott FI, Johnson FR, Bewtra M, Brensinger CM, Roy JA, Reed SD, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Curtis JR, Lewis JD.

Inflamm Bowel Dis. 2018 Dec 9. doi: 10.1093/ibd/izy321. [Epub ahead of print]

PMID:
30535149
3.

Risk maps for cities: Incorporating streets into geostatistical models.

Rose EB, Lee K, Roy JA, Small D, Ross ME, Castillo-Neyra R, Levy MZ.

Spat Spatiotemporal Epidemiol. 2018 Nov;27:47-59. doi: 10.1016/j.sste.2018.08.003. Epub 2018 Aug 29.

PMID:
30409376
4.

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.

Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd.

Open Forum Infect Dis. 2018 Jun 7;5(6):ofy076. doi: 10.1093/ofid/ofy076. eCollection 2018 Jun.

5.

Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.

Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR.

Am J Gastroenterol. 2018 Mar;113(3):405-417. doi: 10.1038/ajg.2017.479. Epub 2018 Jan 16.

6.

Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.

Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI.

Inflamm Bowel Dis. 2017 Dec 19;24(1):217-226. doi: 10.1093/ibd/izx019.

PMID:
29272482
7.

Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs.

Saine ME, Gizaw M, Carbonari DM, Newcomb CW, Roy JA, Cardillo S, Esposito DB, Bhullar H, Gallagher AM, Strom BL, Lo Re V 3rd.

Pharmacoepidemiol Drug Saf. 2018 Oct;27(10):1147-1150. doi: 10.1002/pds.4368. Epub 2017 Dec 18.

PMID:
29250905
8.

Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.

Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Lo Re V 3rd.

Clin Infect Dis. 2017 Oct 16;65(9):1542-1550. doi: 10.1093/cid/cix564.

9.

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.

Lo Re V, Carbonari DM, Saine ME, Newcomb CW, Roy JA, Liu Q, Wu Q, Cardillo S, Haynes K, Kimmel SE, Reese PP, Margolis DJ, Apter AJ, Reddy KR, Hennessy S, Bhullar H, Gallagher AM, Esposito DB, Strom BL.

BMJ Open Diabetes Res Care. 2017 Jul 31;5(1):e000400. doi: 10.1136/bmjdrc-2017-000400. eCollection 2017.

10.

The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.

Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M.

Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.

11.

The Reply.

Lo Re V 3rd, Carbonari DM, Lewis JD, Roy JA, Corley DA.

Am J Med. 2017 Aug;130(8):e369. doi: 10.1016/j.amjmed.2017.03.062. No abstract available.

PMID:
28734384
12.

Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Lo Re V Rd, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA.

Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1172-1181. doi: 10.1002/pds.4258. Epub 2017 Jul 19.

13.

Statistical Methods for Recurrent Event Analysis in Cohort Studies of CKD.

Yang W, Jepson C, Xie D, Roy JA, Shou H, Hsu JY, Anderson AH, Landis JR, He J, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2066-2073. doi: 10.2215/CJN.12841216. Epub 2017 Jul 17. Review.

14.

Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study.

He J, Shlipak M, Anderson A, Roy JA, Feldman HI, Kallem RR, Kanthety R, Kusek JW, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Wolf M, Zhang X, Raj D, Hamm L; CRIC (Chronic Renal Insufficiency Cohort) Investigators.

J Am Heart Assoc. 2017 May 17;6(5). pii: e005336. doi: 10.1161/JAHA.116.005336.

15.

Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.

Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Tate JP, Lim JK, Justice AC, Goetz MB, Corley DA, Lo Re V.

Open Forum Infect Dis. 2017 Jan 28;4(2):ofx012. doi: 10.1093/ofid/ofx012. eCollection 2017 Spring.

16.

High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli.

Rattanaumpawan P, Nachamkin I, Bilker WB, Roy JA, Metlay JP, Zaoutis TE, Lautenbach E; CDC prevention epicenters program.

Ann Clin Microbiol Antimicrob. 2017 Apr 8;16(1):25. doi: 10.1186/s12941-017-0202-4.

17.

Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease.

Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA, Lustigova E, Nessel L, Ford V, Raj D, Porter AC, Soliman EZ, Wright JT Jr, Wolf M, He J; CRIC Investigators.

JAMA Cardiol. 2017 Jun 1;2(6):635-643. doi: 10.1001/jamacardio.2017.0363.

18.

Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.

Hsu JY, Roy JA, Xie D, Yang W, Shou H, Anderson AH, Landis JR, Jepson C, Wolf M, Isakova T, Rahman M, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1181-1189. doi: 10.2215/CJN.10301016. Epub 2017 Feb 27.

19.

Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN).

Lum KJ, Newcomb CW, Roy JA, Carbonari DM, Saine ME, Cardillo S, Bhullar H, Gallagher AM, Lo Re V 3rd.

Eur J Clin Pharmacol. 2017 Jan;73(1):115-123. doi: 10.1007/s00228-016-2148-4. Epub 2016 Oct 27.

PMID:
27787616
20.

Acute Kidney Injury in Pediatric Severe Sepsis: An Independent Risk Factor for Death and New Disability.

Fitzgerald JC, Basu RK, Akcan-Arikan A, Izquierdo LM, Piñeres Olave BE, Hassinger AB, Szczepanska M, Deep A, Williams D, Sapru A, Roy JA, Nadkarni VM, Thomas NJ, Weiss SL, Furth S; Sepsis PRevalence, OUtcomes, and Therapies Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators Network.

Crit Care Med. 2016 Dec;44(12):2241-2250.

21.

A framework for Bayesian nonparametric inference for causal effects of mediation.

Kim C, Daniels MJ, Marcus BH, Roy JA.

Biometrics. 2017 Jun;73(2):401-409. doi: 10.1111/biom.12575. Epub 2016 Aug 1.

22.

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1035-43. doi: 10.1016/j.cgh.2016.03.040. Epub 2016 Apr 5.

23.

Abrupt Decline in Kidney Function Before Initiating Hemodialysis and All-Cause Mortality: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Hsu RK, Chai B, Roy JA, Anderson AH, Bansal N, Feldman HI, Go AS, He J, Horwitz EJ, Kusek JW, Lash JP, Ojo A, Sondheimer JH, Townsend RR, Zhan M, Hsu CY; CRIC Study Investigators.

Am J Kidney Dis. 2016 Aug;68(2):193-202. doi: 10.1053/j.ajkd.2015.12.025. Epub 2016 Jan 29.

24.

Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.

Lo Re V 3rd, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Haynes K, Roy JA, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA.

Am J Med. 2016 Mar;129(3):283-91.e5. doi: 10.1016/j.amjmed.2015.10.029. Epub 2015 Nov 17.

25.

Discordant identification of pediatric severe sepsis by research and clinical definitions in the SPROUT international point prevalence study.

Weiss SL, Fitzgerald JC, Maffei FA, Kane JM, Rodriguez-Nunez A, Hsing DD, Franzon D, Kee SY, Bush JL, Roy JA, Thomas NJ, Nadkarni VM; SPROUT Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators Network.

Crit Care. 2015 Sep 16;19:325. doi: 10.1186/s13054-015-1055-x.

26.

Validity of Primary Immunodeficiency Disease Diagnoses in United States Medicaid Data.

Hernandez-Trujillo H, Orange JS, Roy JA, Wang Y, Newcomb CN, Liu Q, Hennessy S, Lo Re V 3rd.

J Clin Immunol. 2015 Aug;35(6):566-72. doi: 10.1007/s10875-015-0185-x. Epub 2015 Aug 14.

PMID:
26271389
27.

Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN).

Carbonari DM, Saine ME, Newcomb CW, Blak B, Roy JA, Haynes K, Wood J, Gallagher AM, Bhullar H, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd.

Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):999-1003. doi: 10.1002/pds.3844. Epub 2015 Jul 27.

PMID:
26213344
28.

Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study.

Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD.

Ann Intern Med. 2015 Aug 18;163(4):262-70. doi: 10.7326/M14-0960.

29.

Influence of Nephrologist Care on Management and Outcomes in Adults with Chronic Kidney Disease.

Ricardo AC, Roy JA, Tao K, Alper A, Chen J, Drawz PE, Fink JC, Hsu CY, Kusek JW, Ojo A, Schreiber M, Fischer MJ; CRIC Study Investigators.

J Gen Intern Med. 2016 Jan;31(1):22-9. doi: 10.1007/s11606-015-3452-x. Epub 2015 Jul 3.

30.

Surrogate markers for time-varying treatments and outcomes.

Hsu JY, Kennedy EH, Roy JA, Stephens-Shields AJ, Small DS, Joffe MM.

Clin Trials. 2015 Aug;12(4):309-16. doi: 10.1177/1740774515583500. Epub 2015 May 6.

31.

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.

Saine ME, Carbonari DM, Newcomb CW, Nezamzadeh MS, Haynes K, Roy JA, Cardillo S, Hennessy S, Holick CN, Esposito DB, Gallagher AM, Bhullar H, Strom BL, Lo Re V 3rd.

BMC Pharmacol Toxicol. 2015 Apr 2;16:8. doi: 10.1186/s40360-015-0007-z.

32.

Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study.

Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, Singhi SC, Erickson S, Roy JA, Bush JL, Nadkarni VM, Thomas NJ; Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.

Am J Respir Crit Care Med. 2015 May 15;191(10):1147-57. doi: 10.1164/rccm.201412-2323OC. Erratum in: Am J Respir Crit Care Med. 2016 Jan 15;193(2):223-4.

33.

Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.

Rattanaumpawan P, Nachamkin I, Bilker WB, Roy JA, Metlay JP, Zaoutis TE, Lautenbach E; CDC Prevention Epicenters Program.

J Antimicrob Chemother. 2015 May;70(5):1547-51. doi: 10.1093/jac/dku548. Epub 2015 Jan 27.

34.

Empiric potassium supplementation and increased survival in users of loop diuretics.

Leonard CE, Razzaghi H, Freeman CP, Roy JA, Newcomb CW, Hennessy S.

PLoS One. 2014 Jul 16;9(7):e102279. doi: 10.1371/journal.pone.0102279. eCollection 2014.

35.

Standards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus.

Li T, Hutfless S, Scharfstein DO, Daniels MJ, Hogan JW, Little RJ, Roy JA, Law AH, Dickersin K.

J Clin Epidemiol. 2014 Jan;67(1):15-32. doi: 10.1016/j.jclinepi.2013.08.013. Review.

36.

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes.

Neugebauer R, Fireman B, Roy JA, O'Connor PJ.

Diabetes Care. 2013 Nov;36(11):3510-6. doi: 10.2337/dc12-2675. Epub 2013 Jul 22.

37.

Super learning to hedge against incorrect inference from arbitrary parametric assumptions in marginal structural modeling.

Neugebauer R, Fireman B, Roy JA, Raebel MA, Nichols GA, O'Connor PJ.

J Clin Epidemiol. 2013 Aug;66(8 Suppl):S99-109. doi: 10.1016/j.jclinepi.2013.01.016.

38.

Synthesis and growth inhibition activity of fluorinated derivatives of tamoxifen.

Malo-Forest B, Landelle G, Roy JA, Lacroix J, Gaudreault RC, Paquin JF.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1712-5. doi: 10.1016/j.bmcl.2013.01.057. Epub 2013 Jan 26.

PMID:
23403084
39.

Methods for estimating kidney disease stage transition probabilities using electronic medical records.

Luo L, Small D, Stewart WF, Roy JA.

EGEMS (Wash DC). 2013 Dec 18;1(3):1040. doi: 10.13063/2327-9214.1040. eCollection 2013.

40.

Tom Ten Have's contributions to causal inference and biostatistics: review and future research directions.

Small DS, Joffe MM, Lynch KG, Roy JA, Russell Localio A.

Stat Med. 2014 Sep 10;33(20):3421-33. doi: 10.1002/sim.5708. Epub 2012 Dec 17. Review. Erratum in: Stat Med. 2014 Sep 10;33(20):3600.

PMID:
23255088
41.

Bayesian inference for the causal effect of mediation.

Daniels MJ, Roy JA, Kim C, Hogan JW, Perri MG.

Biometrics. 2012 Dec;68(4):1028-36. doi: 10.1111/j.1541-0420.2012.01781.x. Epub 2012 Sep 24.

42.

Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes.

Neugebauer R, Fireman B, Roy JA, O'Connor PJ, Selby JV.

Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:99-113. doi: 10.1002/pds.3253. Erratum in: Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1361.

PMID:
22552985
43.

Value and the medical home: effects of transformed primary care.

Gilfillan RJ, Tomcavage J, Rosenthal MB, Davis DE, Graham J, Roy JA, Pierdon SB, Bloom FJ Jr, Graf TR, Goldman R, Weikel KM, Hamory BH, Paulus RA, Steele GD Jr.

Am J Manag Care. 2010 Aug;16(8):607-14.

44.

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

Verma S, Sehdev S, Joy A, Madarnas Y, Younus J, Roy JA.

Curr Oncol. 2009 Jul;16 Suppl 2:S1-13.

45.

A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function.

White RR, Roy JA, Viles KD, Sullenger BA, Kontos CD.

Angiogenesis. 2008;11(4):395-401. doi: 10.1007/s10456-008-9122-4. Epub 2008 Nov 27.

46.

Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.

Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy JA, Piccart M, Eisenhauer E.

J Clin Oncol. 2004 Nov 15;22(22):4595-603. Epub 2004 Oct 4.

PMID:
15466785
47.

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.

Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W.

Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8.

PMID:
14656271
48.

Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin.

Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, Cheek DJ, Pizzo SV.

Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6656-61. Epub 2001 May 29.

49.

EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.

Hamilton A, Roy JA, Beex L, Piccart M, Mauriac L, Coleman R, Paridaens R, Boes GH, van Vreckem A, Palmer P, Klijn J.

Breast Cancer Res Treat. 2000 Mar;60(2):181-8.

PMID:
10845281
50.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S.

J Natl Cancer Inst. 2000 May 3;92(9):699-708.

PMID:
10793106

Supplemental Content

Support Center